John Ouyang

6.8k total citations · 2 hit papers
67 papers, 4.9k citations indexed

About

John Ouyang is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, John Ouyang has authored 67 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Genetics, 26 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in John Ouyang's work include Genetic and Kidney Cyst Diseases (30 papers), Electrolyte and hormonal disorders (21 papers) and Ion Transport and Channel Regulation (14 papers). John Ouyang is often cited by papers focused on Genetic and Kidney Cyst Diseases (30 papers), Electrolyte and hormonal disorders (21 papers) and Ion Transport and Channel Regulation (14 papers). John Ouyang collaborates with scholars based in United States, Netherlands and Japan. John Ouyang's co-authors include Frank S. Czerwiec, Vicente E. Torres, Arlene B. Chapman, Ronald D. Perrone, Olivier Devuyst, Ron T. Gansevoort, Holly B. Krasa, Eiji Higashihara, Cesare Orlandi and Jared J. Grantham and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

John Ouyang

66 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

2012 1.1k citations Vicente E. Torres, Arlene B. Chapman et al. profile →
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

2017 398 citations Vicente E. Torres, Arlene B. Chapman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Ouyang United States	31	2.2k	2.0k	1.9k	895	753	67	4.9k
Svend Strandgaard Denmark	38	518 0.2×	627 0.3×	1.1k 0.6×	1.2k 1.3×	213 0.3×	135	5.9k
Rainer Rettig Germany	35	131 0.1×	1.1k 0.5×	338 0.2×	269 0.3×	168 0.2×	161	4.1k
Peter Kapeller Austria	33	179 0.1×	294 0.1×	566 0.3×	139 0.2×	418 0.6×	55	4.0k
Fumiki Yoshihara Japan	35	90 0.0×	1.2k 0.6×	664 0.3×	502 0.6×	131 0.2×	132	4.2k
J. Paul Muizelaar United States	48	79 0.0×	1.5k 0.7×	890 0.5×	67 0.1×	221 0.3×	116	9.6k
Martin Hausberg Germany	28	90 0.0×	389 0.2×	538 0.3×	689 0.8×	87 0.1×	85	3.0k
Leanne Groban United States	34	505 0.2×	612 0.3×	199 0.1×	34 0.0×	213 0.3×	129	3.4k
David D. Ørsted Denmark	20	141 0.1×	610 0.3×	249 0.1×	181 0.2×	91 0.1×	32	2.4k
Assumpta Caixàs Spain	31	540 0.2×	381 0.2×	120 0.1×	131 0.1×	87 0.1×	149	2.8k
Yusuke Ohya Japan	32	46 0.0×	846 0.4×	370 0.2×	688 0.8×	403 0.5×	178	3.5k

Countries citing papers authored by John Ouyang

Since Specialization

Citations

This map shows the geographic impact of John Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ouyang more than expected).

Fields of papers citing papers by John Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ouyang. The network helps show where John Ouyang may publish in the future.

Co-authorship network of co-authors of John Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of John Ouyang. A scholar is included among the top collaborators of John Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Ouyang. John Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ouyang, John, et al.. (2025). Titanium Particles Activate Osteocytic Connexin 43 to Induce Oxidative Stress and Osteoclastogenesis Through the JAK-STAT Pathway. Antioxidants and Redox Signaling. 43(4-6). 215–238. 1 indexed citations

Peng, Jian, et al.. (2025). Posterolateral Tibial Plateau Fractures in Adult Anterior Cruciate Ligament Avulsion Effect on Postoperative Knee Function. Orthopaedic Surgery. 17(5). 1359–1368.

Perrone, Ronald D., Dorothee Oberdhan, John Ouyang, et al.. (2023). OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney International Reports. 8(5). 989–1001. 17 indexed citations

Gansevoort, Ron T., Vicente E. Torres, Olivier Devuyst, et al.. (2021). The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial. Journal of the American Society of Nephrology. 32(7). 1801–1812. 7 indexed citations

Higashihara, Eiji, Hiroshi Fukuhara, John Ouyang, et al.. (2020). Estimation of Changes in Kidney Volume Growth Rate in ADPKD. Kidney International Reports. 5(9). 1459–1471. 8 indexed citations

Gansevoort, Ron T., Maatje D.A. van Gastel, Arlene B. Chapman, et al.. (2019). Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney International. 96(1). 159–169. 54 indexed citations

Torres, Vicente E., Olivier Devuyst, Arlene B. Chapman, et al.. (2017). Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology. 45(3). 257–266. 18 indexed citations

Devuyst, Olivier, Arlene B. Chapman, Ron T. Gansevoort, et al.. (2016). Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. Journal of the American Society of Nephrology. 28(5). 1592–1602. 65 indexed citations

Casteleijn, Niek F., Jaime D. Blais, Arlene B. Chapman, et al.. (2016). Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. American Journal of Kidney Diseases. 69(2). 210–219. 29 indexed citations

10.

Marder, Stephen R., Mette Krog Josiassen, Peter Zhang, et al.. (2016). Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatrica. 29(5). 278–290. 29 indexed citations

11.

Verbalis, Joseph G., Howard Ellison, Mary Hobart, et al.. (2016). Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT). American Journal of Kidney Diseases. 67(6). 893–901. 42 indexed citations

12.

Boertien, Wendy E., Esther Meijer, Paul E. de Jong, et al.. (2015). Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. American Journal of Kidney Diseases. 65(6). 833–841. 66 indexed citations

13.

Pang, Peter S., Mihai Gheorghiade, Karl Swedberg, et al.. (2011). Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. American Heart Journal. 161(6). 1067–1072. 28 indexed citations

14.

Irazabal, María V., Vicente E. Torres, Marie C. Hogan, et al.. (2011). Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney International. 80(3). 295–301. 101 indexed citations

15.

Berl, Tomás, Joseph G. Verbalis, Robert W. Schrier, et al.. (2010). Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. Journal of the American Society of Nephrology. 21(4). 705–712. 237 indexed citations

16.

Udelson, James E., Cesare Orlandi, John Ouyang, et al.. (2008). Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction. Journal of the American College of Cardiology. 52(19). 1540–1545. 139 indexed citations

17.

Rossi, Joseph S., Melike Bayram, James E. Udelson, et al.. (2007). Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care. 9(2). 82–86. 123 indexed citations

18.

Orlandi, Cesare, Wendy Gattis Stough, Uri Elkayam, et al.. (2006). Comparison of 60-Day Mortality in Hospitalized Heart Failure Patients With Versus Without Hypothermia. The American Journal of Cardiology. 98(11). 1485–1488. 12 indexed citations

19.

O’Connor, Christopher M., Kirkwood F. Adams, Wendy A. Gattis, et al.. (2004). 1069-119 Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF trial. Journal of the American College of Cardiology. 43(5). A181–A181. 4 indexed citations

20.

Udelson, James E., Cesare Orlandi, Terrence X. O’Brien, et al.. (2002). Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. Journal of the American College of Cardiology. 39. 156–156. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact